

**PREVENTION AND CONTROL OF HAEMOPHILUS INFLUENZAE TYPE B DISEASE
RECOMMENDATIONS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
(ACIP)**

WB2384

FACULTY/

CREDENTIALS:

Elizabeth C Briere, MD, MPH, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

Thomas Andrew Clark, MD, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

Amanda Cohn, MD, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

Nancy Messonnier, MD, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

Perdo L. Moro, MD, MPH, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC

Lorry G Rubin, MD, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York

DATE/TIME: February 21, 2014

ORIGINATION/ EXPIRATION DATES: February 21, 2014
February 21, 2016

URL: <http://www.cdc.gov/mmwr>

HARDWARE/SOFTWARE: Computer-Internet;

MATERIALS: Access to computer

TARGET AUDIENCE: Physicians, Registered Nurses, public health community

PREREQUISITES: Knowledge of vaccines and related agents for the control of vaccine-preventable diseases

PROGRAM DESCRIPTION:

This report is designed to update information on Hib epidemiology in the United States and summarizes currently available Hib vaccines and current ACIP recommendations on prevention and control of Hib disease in immunocompetent and high-risk populations; it does not contain new recommendations and is intended as a resource for clinicians.

OBJECTIVES:

At the conclusion of the session, the participant will be able to:

1. Describe the epidemiology of Hib disease in the United States
2. Identify recommendations for Hib vaccination in children and special populations in the United States
3. Describe chemoprophylaxis measures that should be implemented around cases of Hib disease

CONTACT INFORMATION: Office of Elizabeth C. Briere, (404) 639-0732

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this MMWR Journal for a maximum of **1.75 AMA PRA Category 1 Credits™**. Physicians *should claim only the credit commensurate with the extent* of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.5** contact hours.

CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer **0.2** ANSI/IACET CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, designated providers of continuing education contact hours (CECH) in health education by the

National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to **1.5** total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are **0**. CDC provider number **GA0082**.

DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of current licensed and available Hib conjugate vaccines are licensed for children 6 weeks through 71 months of age, depending on vaccine product. Hib vaccines are recommended for persons >71 months of age with certain medical risk factors.

CDC does not accept commercial support.

SUPPORT/FUNDING: CDC

METHOD OF PARTICIPATION:

You may participate in the educational activity by viewing the program information above.

To evaluate this educational activity, receive a certificate/statement of credit/contact hours, to print-out an on-going transcript of all your TCEOnline CE activities for credits/contact hours, please go to: www.cdc.gov/TCEOnline.

FEES: No fees are charged for CDC's CE activities.